Exclusive Summary

• A First-in-Class topical Kv1.3 inhibitor with a highly selective mechanism of action, promising a superior safety profile that circumvents the long-term side effects of corticosteroids and the black box warnings of JAK inhibitors.
• Uniquely positioned to address the significant unmet need for a safe and effective long-term treatment for mild-to-moderate atopic dermatitis, particularly filling a major gap for the highly sensitive pediatric and infant patient population.
• A de-risked asset with completed Phase 1 and ongoing Phase 2a clinical studies confirming its excellent human safety, tolerability, and negligible systemic drug absorption (<LLOQ).
• Possesses a distinct competitive edge with preclinical data showing efficacy comparable or superior to current non-steroidal benchmarks, and with a clear lead as the most advanced topical candidate in its class, it has strong potential to be Best-in-Class.

Asset Materials

Contact Us for Full Materials